Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
Open accessThe DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
“UGT1A1 was one of the first factors to be investigated, due to the observation of severe toxicities in patients with inherited disorders characterized by decreased bilirubin glucuronidation like Gilbert’s syndrome (i.e. mild unconjugated hyperbilirubinemia) [Wasserman et al. 1997a].”
BackgroundPharmacogenomics of human UDP-glucuronosyltransferase enzymes
Guillemette, C. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500171 · Cited by 425
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“in Gilbert’s syndrome, are at higher risk for severe toxicity when treated with irinotecan [48].”
BackgroundIrinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Glucuronidation in Humans: Pharmacogenetic and Developmental Aspects
de Wildt, S. N., Kearns, G. L., Leeder, J. S., & van den Anker, J. N. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00005 · Cited by 393
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
IYER, L., HALL, D., DAS, S., MORTELL, M., RAMIREZ, J., KIM, S., DIRIENZO, A., & RATAIN, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70078-0 · Cited by 356
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Flaig, T. W., Gustafson, D. L., Su, L.-J., Zirrolli, J. A., Crighton, F., Harrison, G. S., Pierson, A. S., Agarwal, R., & Glodé, L. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9019-2 · Cited by 315
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., & Baiget, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602042 · Cited by 315
Inherited disorders of bilirubin metabolism
Bosma, P. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00359-8 · Cited by 279
Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity
Rouits, E., Boisdron-Celle, M., Dumont, A., Guérin, O., Morel, A., & Gamelin, E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0548 · Cited by 276
Metadata
- Authors
- Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., & Cvitkovic, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 1997-10
- Volume
- 8
- Issue
- 10
- Pages
- 1049-1051
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2137613776
- Cited by
- 213
- References
- 0
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.